Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by means of total, lean and different adipose factors dosing body weight using bayesian and non-linear least squares methods

International Journal of Clinical Pharmacology Research

Volumn 16, Issue 4-5, 1996, Pages 89-97

  Wu, G ^a   Furlanut, M ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEAN BODY WEIGHT; MALE; MULTIDRUG RESISTANCE; REGRESSION ANALYSIS;

ADULT; BAYES THEOREM; BIAS (EPIDEMIOLOGY); BODY WEIGHT; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEAST-SQUARES ANALYSIS; LINEAR MODELS; MALE; MIDDLE AGED; SEX FACTORS; SOFTWARE;

EID: 0030428916     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Faulds D., Goa K.L., Benfield P. Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders Drugs, 45, 953-1040, 1993
2. Morgan D.L., Bray K.M. Lean body mass as a predictor of drug dosage. Clin. Pharmacokinet, 26, 292-307, 1994
3. Lucey M.R. et al. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 III A Lancet, 335, 11-15, 1990.
4. Ryffel B., Foxwell B.M.J., Mihatsch M.J., Donatsch P., Maurer G. Biologic significance of cyclosporine metabolites. Transplant. Proc., 20(suppl. 2), 575-584, 1988
5. Yatscoff R.W., Rosano T.G., Bowers L.D. The clinical significance of cyclosporine metabolites. Clin. Biochem., 24, 23-35, 1991
6. Chymol G Clinical pharmacokinetics of drugs in obesity An update. Clin. Pharmacokinet, 25, 103-114, 1993.
7. Yee G.C., McGuire T.R., Gmur D.J., Lennon T.P., Deeg H.J. Blood cyclosporin pharmacokinetics in patients undergoing marrow transplantation influence of age, obesity and hematocrit Transplantation, 43, 399-402, 1988
8. Flechner S.M., Kolbeinsson M.E., Tam J., Lum B. The impact of body weight on cyclosporine pharmacokinetics in renal transplant recipients. Transplantation, 47, 806-810, 1989.
9. Waters M.R., Albano J.D.M., Schaman V.L., Venkat Raman G Pharmacokinetics of cyclosporin in man following a single oral dose: relationship to body lat content. Nephrol Dial. Transplant., 4, 71-74, 1989.
10. Buffington D.E., Lampasona V Chandler M.H.H. Computers in pharmacokinetics: choosing software for clinical decision making. Clin. Pharmacokinet., 25, 205-216, 1993.
11. Mungall D., Heissler J., Kallenbach M. Computer applications in clinical pharmacokinetics and pharmacodynamics In: Derendorf H., Hochhaus G., eds. "Handbook of pharmacokinetic/ pharmacodynamic correlation." CRC Press. London, 1995, pp. 415-463.
12. Schumacher G.E., Barr J.T. Bayesian approaches in pharmacokinetics Clin. Pharm . 3, 525-530, 1984.
13. Thomson A.M., Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin. Pharmacokinetic., 22, 447-467, 1992.
14. Abbottbase Pharmacokinetic System Operations Manual. Abbott Park. Illinois, 1992, pp. 6-44 & 6-45.
15. Moor J A.M., Graybill FA, Boes D.C. "Introduction to the theory of statistics". 3rd ed., McGraw-Hill Book Company, London 1988, p. 36
16. Wu G., et al. Prediction of cyclosporine blood concentrations in hematological patients with multidrug resistance Pharmacol Res., 31(suppl), 44, 1995.
17. Wu G., Baraldo M., Pea F., Cossettini P., Furlanut M. Effects of different sampling strategies on predictions of blood cyclosporine concentrations in haematological patients with multidrug resistance by Bayesian and non-linear least squares methods. Pharmacol Res., 32, 355-362, 1995
18. Wu G., Cossettini P., Furlanut M. Prediction of blood cyclosporine concentrations in haematological patients with multidrug resistance by one- two- and three-compartment models using Bayesian and non-linear least squares methods. Pharmacol. Res., 34,47-57, 1996.
19. Wu G., Furlanut M., Pea F., Cossettini P. Effect of number of samples on Bayesian and non-linear least squares individualisation: a study of haematological patients with multidrug resistance treated with cyclosporine. Pharmacol. Res. (3rd revised)
20. Rodvold K.A., Rotschafer J.C., Gilliand S.S., Guay D.R.P., Vance-Bryan K. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies. Ther. Drug Monit., 16, 37-41, 1994.
21. Pryka R.D., Rodvold K.A., Garrison M., Rotschafer J.C. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models. Ther. Drug Monit., 11, 450-454, 1989.
22. Rodvold K.A., Pryka R.D., Garrison M., Rotschafer J. C. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations. Ther. Drug Monit., 11, 269-275, 1989
23. Abernethy D.R., Greenblatt D.J. Drug disposition in obese humans - an update. Clin. Pharmacokinet., 11, 195-213, 1986.
24. Moyer T.P., Winkels J., Krom R., Wiesner R. Evaluation of Abbott TDx monoclonal assay for monitoring cyclosporine in whole blood [Tech Brief]. Clin. Chem., 37, 1120-1121, 1991.
25. Abbottbase Pharmacokinetic System Operations Manual. Abbott Park, Illinois, 1992, p. 6-68.
26. Abbottbase Pharmacokinetic System Operations Manual. Abbott Park, Illinois, 1992. p. 3-54.
27. Anderson J.E. et al. Evaluation of a Bayesian approach to the pharmacokinetic interpretation of cyclosporin concentrations in renal allograft recipients. Ther. Drug Monit., 16, 160-165, 1994
28. Cantarovich F et al. Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy. Transplantation, 45, 389-394, 1988.
29. Grevel J., Kahan B.D. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosponne therapy. Clin. Chem., 37, 1905-1908, 1991.
30. Johnston A. et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc., 22, 1345-1346, 1990.
31. Meyer M., Bennet W., Udeajan J., Munar M. Evaluation of the efficacy of area under the curve (AUC) cyclosporine (CSA) monitoring. J. Am. Soc. Nephrol., 2, 808, 1991.
32. Wu G., Baraldo M., Furlanut M. Calculating percentage prediction error: a user's note. Pharmacol. Res., 32, 241-248, 1995.
33. Wu G. Prediction of uptake of methyl mercury by rat erythrocytes using a two-compartment model. Arch. Toxicol. 70, 34-42, 1995.
34. Healy M.J.R. Outliers in clinical chemistry quality-control schemes. Clin. Chem., 25, 675-677, 1979.
35. Sheiner LB., Beal S.L. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm., 9, 503-512, 1931.
36. Wu G. Calculating predictive performance: a users note. Pharmacol Res., 31, 393-399, 1995.
37. Kelman A.W., Whiting B., Bryson S.M. OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics. Br. J. Clin. Pharmacol., 14, 247-256, 1982.
38. Walpole R.E., Myers R.H. "Probability and statistics for engineers and scientists." 4th ed., Macmillan, New York, 1989, p. 201.
39. Jelliffe R.W. et al. Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control. Ther. Drug Monit., 15, 380-393, 1993.